Barreto-Galvez Angelica, Niljikar Mrunmai, Gagliardi Julia, Zhang Ranran, Kumar Vasudha, Juruwala Aastha, Pradeep Archana, Shaikh Anam, Tiwari Priyanka, Sharma Kritika, Gerhardt Jeannine, Cao Jian, Kataoka Keisuke, Durbin Adam, Qi Jun, Ye B Hilda, Madireddy Advaitha
bioRxiv. 2023 Apr 29:2023.04.29.538781. doi: 10.1101/2023.04.29.538781.
Mutations in the epigenetic regulator and global transcriptional activator, E1A binding protein (EP300), is being increasingly reported in aggressive hematological malignancies including adult T-cell leukemia/lymphoma (ATLL). However, the mechanistic contribution of EP300 dysregulation to cancer initiation and progression are currently unknown. Independent inhibition of EP300 in human cells results in the differential expression of genes involved in regulating the cell cycle, DNA replication and DNA damage response. Nevertheless, specific function played by EP300 in DNA replication initiation, progression and replication fork integrity has not been studied. Here, using ATLL cells as a model to study EP300 deficiency and an p300-selective PROTAC degrader, degrader as a pharmacologic tool, we reveal that EP300-mutated cells display prolonged cell cycle kinetics, due to pronounced dysregulations in DNA replication dynamics leading to persistent genomic instability. Aberrant DNA replication in EP300-mutated cells is characterized by elevated replication origin firing due to increased replisome pausing genome-wide. We demonstrate that EP300 deficiency results in nucleolytic degradation of nascently synthesized DNA at stalled forks due to a prominent defect in fork stabilization and protection. This in turn results in the accumulation of single stranded DNA gaps at collapsed replication forks, in EP300-deficient cells. Inhibition of Mre11 nuclease rescues the ssDNA accumulation indicating a dysregulation in downstream mechanisms that restrain nuclease activity at stalled forks. Importantly, we find that the absence of EP300 results in decreased expression of BRCA2 protein expression and a dependency on POLD3-mediated error-prone replication restart mechanisms. The overall S-phase abnormalities observed lead to under-replicated DNA in G2/M that instigates mitotic DNA synthesis. This in turn is associated with mitotic segregation defects characterized by elevated micronuclei formation, accumulation of cytosolic DNA and transmission of unrepaired inherited DNA lesions in the subsequent G1-phase in EP300-deficient cells. We demonstrate that the DNA replication dynamics of EP300-mutated cells ATLL cells recapitulate features of BRCA-deficient cancers. Altogether these results suggest that mutations in EP300 cause chronic DNA replication stress and defective replication fork restart results in persistent genomic instability that underlie aggressive chemo-resistant tumorigenesis in humans.
表观遗传调节因子和全局转录激活因子E1A结合蛋白(EP300)的突变在包括成人T细胞白血病/淋巴瘤(ATLL)在内的侵袭性血液系统恶性肿瘤中的报道越来越多。然而,目前尚不清楚EP300失调对癌症发生和进展的机制性作用。在人类细胞中独立抑制EP300会导致参与调节细胞周期、DNA复制和DNA损伤反应的基因差异表达。尽管如此,EP300在DNA复制起始、进展和复制叉完整性中所起的特定功能尚未得到研究。在这里,我们以ATLL细胞为模型研究EP300缺陷,并使用p300选择性PROTAC降解剂作为药理工具,我们发现EP300突变的细胞表现出延长的细胞周期动力学,这是由于DNA复制动力学的明显失调导致持续的基因组不稳定。EP300突变细胞中的异常DNA复制的特征是由于全基因组复制体停顿增加导致复制起点激发增加。我们证明,由于叉稳定和保护方面的突出缺陷,EP300缺陷导致停滞叉处新生合成DNA的核酸降解。这反过来又导致EP300缺陷细胞中塌陷复制叉处单链DNA缺口的积累。抑制Mre11核酸酶可挽救ssDNA积累,表明下游机制失调,这些机制抑制了停滞叉处的核酸酶活性。重要的是,我们发现EP300的缺失导致BRCA2蛋白表达降低,并依赖于POLD3介导的易出错复制重启机制。观察到的总体S期异常导致G2/M期DNA复制不足,从而引发有丝分裂DNA合成。这反过来又与有丝分裂分离缺陷相关,其特征是微核形成增加、胞质DNA积累以及EP300缺陷细胞随后G1期未修复的遗传DNA损伤的传递。我们证明,EP300突变的ATLL细胞的DNA复制动力学概括了BRCA缺陷癌症的特征。总之,这些结果表明,EP300突变导致慢性DNA复制应激,复制叉重启缺陷导致持续的基因组不稳定,这是人类侵袭性化疗耐药肿瘤发生的基础。